Impact of lower achieved blood pressure on outcomes in hypertensive patients

Journal of Hypertension

Volumn 30, Issue 4, 2012, Pages 802-810

  Okin, Peter M ^a   Hille, Darcy A ^b   Kjeldsen, Sverre E ^c,d   Dahlöf, Björn ^e   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

electrocardiogram; hypertension; hypertrophy

Indexed keywords

ATENOLOL; LOSARTAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 84858709219     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283516499     Document Type: Article

References (40)

1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355:1955-1964.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560-2572. (Pubitemid 37430158)
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
6. Zanchetti A, Mancia G, Black HR, Oparil S, Waeber B, Schmieder RE, et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009; 27:673-679.
7. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
8. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61-68.
9. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in nondiabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374:525-533.
10. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31:2115-2127.
11. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension 2010; 56:196-202.
12. Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918-929.
13. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Porcellati C. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy. J Am Coll Cardiol 1998; 31:383-390. (Pubitemid 28153459)
14. Verdecchia P, Reboldi G, Angeli F, Avanzini F, de Simone G, Pede S, et al. Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: The HEART Survey Study. Am J Hypertens 2007; 20:997-1004. (Pubitemid 47313620)
15. Fagard RH, Staessen JA, Thijs L, Celis H, Birkenhager WH, Bulpitt CJ, et al. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004; 44:459-464. (Pubitemid 39281496)
16. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and prediction of major cardiovascular events: The LIFE Study. JAMA 2004; 292:2343-2349. (Pubitemid 39491918)
17. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, et al. Reduction of electrocardiographic left ventricular hypertrophy is associated with decreased heart failure hospitalization in hypertensive patients. Ann Intern Med 2007; 147:311-319. (Pubitemid 351664558)
18. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation: the LIFE Study. JAMA 2006; 296:1242-1248. (Pubitemid 44394895)
19. Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007; 116:700-705. (Pubitemid 47260463)
20. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
21. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study: rationale, design, and methods. Am J Hypertens 1997; 10:705-713. (Pubitemid 27313815)
22. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltageduration products. J Am Coll Cardiol 1995; 25:417-423.
23. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37:161-186.
24. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a timevarying covariate with an extended Kaplan-Meier estimate. Am Statistician 2005; 59:301-307. (Pubitemid 41616828)
25. Pastor-Barriuso R, Banegas JR, Damián J, Appel LJ, Guallar E. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731-739.
26. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension (Review). Cochrane Database Syst Rev 2009; CD004349.
27. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-1369.
28. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertension: The LIFE Study. Eur Heart J 2010; 31:2271-2279.
29. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP, for the INDANA Project Steering Committee. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a metaanalysis of individual-patient data. Ann Intern Med 2002; 136:438-448. (Pubitemid 34234783)
30. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary disease be dangerous? Ann Intern Med 2006; 144:884-893. (Pubitemid 46768128)
31. Bangalore S, Messerli FH, Wun C-C, Zuckerman AL, DeMicco D, Kostis JB. LaRosa JC, and Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. Eur Heart J 2010; 31:2897-2908.
32. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J 2010; 31:2837-2840.
33. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kenge A-P, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29:4-16.
34. Gerdts E, Franklin S, RieckA° , Papademetriou V, Wachtell K, Nieminen M, et al. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). Blood Pressure 2009; 18:180-186.
35. Viberti G, Morgensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria: European Microalbuminuria Captopril Study Group. JAMA 1994; 271:275-279. (Pubitemid 24030753)
36. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al. Effects of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299:1678-1689. (Pubitemid 351519865)
37. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
38. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3. 4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33:983-990.
39. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation 2010; 122:844-846.
40. Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Human Hypertens 2004; 18:367-373.